Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax compare to intensive chemotherapy (IC) in patients who are ‘fit’ or ‘unfit’ for IC. We compared outcomes of older patients with ne...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Am J Hematol
Huvudupphovsmän: Maiti, Abhishek, Qiao, Wei, Sasaki, Koji, Ravandi, Farhad, Kadia, Tapan M., Jabbour, Elias J., Daver, Naval G., Borthakur, Gautam, Garcia-Manero, Guillermo, Pierce, Sherry A., Montalbano, Kathryn S., Pemmaraju, Naveen, Naqvi, Kiran, Ohanian, Maro, Short, Nicholas J., Alvarado, Yesid, Takahashi, Koichi, Yilmaz, Musa, Jain, Nitin, Kornblau, Steven M., Andreeff, Michael, Bose, Prithviraj, Ferrajoli, Alessandra, Issa, Ghayas C., Masarova, Lucia, Thompson, Philip A., Rausch, Caitlin R., Ning, Jing, Kantarjian, Hagop M., DiNardo, Courtney D., Konopleva, Marina Y.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128145/
https://ncbi.nlm.nih.gov/pubmed/33264443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.26061
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk